Pfeiffer 1998.
| Methods | Randomised Phase II trial March 1990 to May 1994 |
|
| Participants | 28 women with recurrent or advanced cervical cancer | |
| Interventions | Arm 1: carboplatin 400 mg/m2 iv d1 q28 Arm 2: teniposide 125 mg/m2 iv d1‐3 q28 |
|
| Outcomes | Response rates OS PFS Toxicity (WHO) |
|
| Notes | 2 patients ineligible (1 severe renal impairment, 1 poor performance status). No ITT analysis performed | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Not documented |
| Allocation concealment (selection bias) | Unclear risk | Not documented |
| Blinding (performance bias and detection bias) All outcomes | Unclear risk | Not documented but OS unlikely to be affected by blinding |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | No missing data |
| Selective reporting (reporting bias) | Low risk | Published report included all pre‐specified outcomes |
| Other bias | Low risk | No hint at any other possible biases |